SITC 2021 | CAMILLA: Phase I/II study of cabozantinib plus durvalumab in advanced GE cancer and GI malignancies

Anwaar Saeed, MD, University of Kansas Medical Center, Kansas City, MO, discusses the Phase Ib results of CAMILLA (NCT03539822), a Phase I/II trial of cabozantinib plus durvalumab in advanced gastric cancer, esophageal adenocarcinoma, hepatocellular carcinoma, and colorectal cancer. Patients with gastric, colorectal, and esophageal cancer acheived an overall response rate (ORR) of 27%, a median progression-free survival (PFS) of 4.5 months, and a median overall survival (OS) of 9 months. Roughly 50% of patients had a PD-L1 combined positive score (CPS) of 5 or above. These patients acheived better ORR and OS results than the general cohort, with a median PFS of 6 months. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.